Table 1 Updates in ovarian cancer drug discovery demonstrating positive phase II activity
Category | Agent/patent (manufacturer) | Mechanism of action | |
|---|---|---|---|
Targeted agents | VEGF-dependent angiogenesis inhibition | Cediranib (AZD2171)/US20070135462 (AstraZeneca) | Oral VEGFR-1,-2,-3 tyrosine kinase inhibitor |
Nintedanib (BIBF1120)/US20140018405 (Boehringer Ingelheim) | Oral VEGFR, PDGFR, FGFR tyrosine kinase inhibitor | ||
PARP inhibitors | Olaparib (AZD2281)/US2010098763 (AstraZeneca) | Oral Poly (ADP-ribose) polymerase-1,-2 inhibitor | |
Rucaparib (CO-338)/US8765751 (Clovis Oncology) | Oral Poly (ADP-ribose) polymerase-1,-2 inhibitor | ||
Niraparib (MK-4827)/US20120035244 (Merck) | Oral Poly (ADP-ribose) polymerase-1,-2 inhibitor | ||
MEK inhibitors | Selumetinib (AZD6244)/US8193229 (Array BioPharma/AstraZeneca) | Oral inhibitor of MEK-1,-2 | |
Binimetinib (MEK162)/US20130273061 (Array BioPharma/Novartis) | Oral inhibitor of MEK-1,-2 | ||
Cytotoxic agents | Â | Etirinotecan pegol (NKTR-102)/US20090074704 (Nektar) | Inhibits Topoisomerase I (IV) |
| Â | Paclitaxel poliglumex (CT2103)/US20070167349 (CTI BioPharma) | Mitotic inhibitor (IV) | |
Lurbinectedin (PM1183)/US20130266666 (PharmaMar) | Marine-derived DNA minor groove binder (IV) | ||
Therapeutic vaccines | Â | Catumaxomab/US20120095192 (Trion Pharma) | Oral tri-functional antibody binds EpCAM, CD3, and Fc receptor |